KLOW is a four-component preparation: GHK-Cu, BPC-157, TB-500 and KPV. It is the GLOW combination with KPV added.
What KPV adds
KPV is the C-terminal tripeptide of alpha-MSH, studied for NF-kappaB-associated anti-inflammatory signalling and notably active at least partly independent of melanocortin receptors. Full detail in our KPV guide.
Its inclusion adds an inflammatory-signalling arm to a combination otherwise centred on matrix, angiogenic and actin-dynamic mechanisms.
Four mechanisms, one vial
The same interpretive caution applies as with any blend, more so with four components. Each acts through a different route; all four are documented individually. The combination itself has not been characterised as a single pharmacological entity, and interactions between components are not described.
Useful where multiple signalling arms are examined together. Not appropriate where an effect needs attributing to a specific mechanism.
Supplied lyophilised. See our reconstitution protocol for handling technique and diluent selection.
Every batch ships with a third-party certificate of analysis. View KLOW and its current COA.
Research use only
Isla Longevity supplies this compound for laboratory research use only. It is not approved by the FDA for human or veterinary use and is not for human consumption. This article summarises published research and is not medical guidance.
